dAxAs
Daxas is the brand name for roflumilast, a selective phosphodiesterase-4 (PDE-4) inhibitor used in adults to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in those with severe COPD associated with chronic bronchitis. It is not a bronchodilator and is intended to be used in addition to inhaled therapies such as long-acting bronchodilators and inhaled corticosteroids.
Mechanism of action and use: Roflumilast works by inhibiting PDE-4, which increases cyclic adenosine monophosphate (cAMP)
Administration and dosing: Daxas is taken orally once daily. The usual dose is 500 micrograms per day,
Side effects and safety: Common adverse effects include nausea, diarrhea, weight loss, headache, and insomnia. Psychiatric
Interactions: Roflumilast is metabolized by CYP3A4 and CYP1A2. Concomitant use with strong inhibitors or inducers of